Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2025)

Barinthus Biotherapeutics' FCF Margin history spans 6 years, with the latest figure at 1814600.0% for Q2 2025.

  • For Q2 2025, FCF Margin changed N/A year-over-year to 1814600.0%; the TTM value through Dec 2025 reached 15147.0%, down 1494771.0%, while the annual FY2024 figure was 199.29%, 682540.0% up from the prior year.
  • FCF Margin reached 1814600.0% in Q2 2025 per BRNS's latest filing, down from 4715.82% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 839600.0% in Q4 2021 to a low of 1814600.0% in Q2 2025.
  • Average FCF Margin over 5 years is 80415.03%, with a median of 1213.89% recorded in 2023.
  • Peak YoY movement for FCF Margin: soared 84103814bps in 2021, then plummeted -83986734bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 839600.0% in 2021, then plummeted by -100bps to 267.34% in 2022, then crashed by -1575bps to 4477.84% in 2023, then surged by 97bps to 122.33% in 2024, then plummeted by -1483230bps to 1814600.0% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's FCF Margin are 1814600.0% (Q2 2025), 4715.82% (Q1 2025), and 122.33% (Q3 2024).